Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A phase 3 trial found that sacituzumab tirumotecan (sac-TMT) significantly extended survival in patients with advanced or recurrent endometrial cancer who had already received platinum-based chemo and immunotherapy. Compared to standard chemotherapy, sac-TMT cut the risk of death by 32% and disease progression by 41%. The FDA has granted priority review to the drug, with a decision expected by June 2027.
A new antibody-drug conjugate (ADC) is showing strong promise for patients with advanced endometrial cancer who've run out of standard options. The phase 3 TroFuse-005 trial found that sacituzumab tirumotecan (sac-TMT) — which targets TROP2, a protein overexpressed in over 90% of endometrial cancers — significantly outperformed chemotherapy in patients previously treated with both platinum-based chemo and immunotherapy.
The results were compelling enough that the FDA has accepted a priority review application for sac-TMT, with a target decision date of June 15, 2027. Researchers called it a potential "new standard of care" for this hard-to-treat population.
By the Numbers:
Why it matters: Patients with recurrent endometrial cancer who've already progressed on chemo and immunotherapy have very limited options. Sac-TMT's survival benefit — even in a population where more control-arm patients received subsequent therapies — signals a meaningful step forward for a disease with few second-line solutions.
